No connection

Search Results

WORX

BEARISH
$1.0 Live
SCWorx Corp. · NASDAQ
$0.76 52W Range $13.05
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 24, 2026
Market cap
$1.07M
P/E
N/A
ROE
-76.3%
Profit margin
-154.4%
Debt/Equity
0.02
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
SCWorx Corp exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is experiencing a catastrophic price collapse, with a 5-year decline of 99.7% and a recent 1-month drop of 47.5%. Despite a low debt-to-equity ratio and modest revenue growth of 13.8%, the profit margin of -154.44% and an ROE of -76.35% demonstrate an unsustainable business model that is rapidly eroding shareholder equity.

Key Strengths

Low Debt/Equity ratio (0.02)
Positive YoY Revenue Growth (13.80%)
Current Ratio of 2.72 suggests short-term liquidity
Quick Ratio of 2.63 indicates minimal reliance on inventory for liquidity
Positive Gross Margin (31.96%)

Key Risks

Extreme negative profitability (Profit Margin -154.44%)
Severe capital erosion (5Y Change -99.7%)
Piotroski F-Score of 1/9 indicates failing financial health
Lack of analyst coverage and institutional support
Bearish technical trend (0/100) suggesting continued downward momentum

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
12
Weak
Value
20
Future
25
Past
5
Health
10
Dividend
0
AI Verdict
Critical Distress
Key drivers: Catastrophic price performance, Severe operational losses, Failing Piotroski score
Confidence
90%
Value
20/100

Ref P/E, PEG, Graham Number

Positives
  • Low Price/Sales ratio (0.37)
Watchpoints
  • No P/E or Graham Number due to lack of earnings
  • Price/Book of 1.94 is high for a company with negative ROE
Future
25/100

Ref Growth rates

Positives
  • Modest revenue growth (13.8%)
Watchpoints
  • Growth is insufficient to offset massive operating losses
  • Negative earnings growth
Past
5/100

Ref Historical trends

Positives
No standout positives identified.
Watchpoints
  • 5Y Change -99.7%
  • 1Y Change -89.0%
  • Consistent value destruction
Health
10/100

Ref Altman Z-Score, Piotroski F-Score

Positives
  • Low absolute debt
Watchpoints
  • Piotroski F-Score 1/9
  • ROE -76.35%
  • ROA -8.42%
Dividend
0/100

Ref Yield, Payout

Positives
No standout positives identified.
Watchpoints
  • No dividend history
  • Zero payout capacity

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$1.0

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for WORX and closest competitors.

Updated 2026-04-23
WOR
SCWorx Corp.
Primary
5Y
-99.7%
3Y
-98.7%
1Y
-89.0%
6M
-75.4%
1M
-47.5%
1W
-10.7%
LYR
Lyra Therapeutics, Inc.
Peer
5Y
-99.9%
3Y
-99.5%
1Y
-87.8%
6M
-91.8%
1M
-50.8%
1W
+32.6%
NIV
NewGenIvf Group Limited
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-99.8%
6M
-98.0%
1M
-6.4%
1W
+9.4%
WOK
WORK Medical Technology Group LTD
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-100.0%
6M
-99.7%
1M
+4.0%
1W
+0.4%
ONC
Onconetix, Inc.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-97.2%
6M
-95.7%
1M
-70.5%
1W
-32.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
1.94
P/S Ratio
0.37
EV/Revenue
-0.13
EV/EBITDA
0.39
Market Cap
$1.07M

Profitability

Profit margins and return metrics

Profit Margin -154.44%
Operating Margin -25.01%
Gross Margin 31.96%
ROE -76.35%
ROA -8.42%

Growth

Revenue and earnings growth rates

Revenue Growth +13.8%
Earnings Growth N/A
Q/Q Revenue Growth +13.78%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.02
Low debt
Current Ratio
2.72
Strong
Quick Ratio
2.63
Excellent
Cash/Share
$1.54

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
45.6%
Op. Margin
-25.0%
Net Margin
-97.4%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.10x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
124%

Healthcare Sector Comparison

Comparing WORX against 548 companies in the Healthcare sector (30 bullish, 163 neutral, 355 bearish)
Return on Equity (ROE)
-76.35%
This Stock
vs
-89.9%
Sector Avg
-15.1% (Below Avg)
Profit Margin
-154.44%
This Stock
vs
-16.4%
Sector Avg
+841.7% (Superior)
Debt to Equity
0.02
This Stock
vs
2.71
Sector Avg
-99.2% (Less Debt)
Revenue Growth
13.8%
This Stock
vs
126.74%
Sector Avg
-89.1% (Slower)
Current Ratio
2.72
This Stock
vs
4.53
Sector Avg
-39.9% (Weaker)

Similar Companies

Peer comparison within the same industry

WORX SCWorx Corp.
BEARISH
Mkt Cap
$1M
P/E
-
ROE
-76.3%
Price
$1.0
LYRA Lyra Therapeutics, Inc.
BEARISH
Mkt Cap
$1M
P/E
-
ROE
-6595.0%
Price
$0.65
 Compare with WORX
NIVF NewGenIvf Group Limited
BEARISH
Mkt Cap
$1M
P/E
0.1
ROE
79.4%
Price
$2.19
 Compare with WORX
WOK WORK Medical...
BEARISH
Mkt Cap
$2M
P/E
-
ROE
-6.5%
Price
$1.18
 Compare with WORX
ONCO Onconetix, Inc.
BEARISH
Mkt Cap
$1M
P/E
-
ROE
-115.5%
Price
$0.76
 Compare with WORX

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
CURRENT REPORT
2026-04-10

WORX filed a current report on April 10, 2026, likely announcing its first-quarter financial results.

8-K
CURRENT REPORT
2026-04-07

WORX filed a current report on April 7, 2026, likely announcing its first-quarter financial results.

10-K
ANNUAL REPORT
2026-03-31

WORX filed its 10-K annual report on March 31, 2026. The provided excerpts do not contain specific financial highlights or detailed risk factors.

S-1
REGISTRATION STATEMENT
2026-01-08

WORX filed an S-1 registration statement on January 8, 2026, indicating its intent to initiate an initial public offering.

8-K
CURRENT REPORT
2025-12-10
10-Q
QUARTERLY REPORT
2025-11-12

WORX filed its 10-Q quarterly report on November 12, 2025. While the filing includes a section for risk factors under Item 1A, no specific financial highlights or detailed risk descriptions were provided in the available excerpts.

DEF 14A
DEFINITIVE PROXY STATEMENT.
2025-10-24

WORX filed a Definitive Proxy Statement (DEF 14A) on October 24, 2025, providing shareholders with necessary information to vote on corporate matters.

8-K
CURRENT REPORT
2025-10-14
8-K
CURRENT REPORT
2025-09-19
10-Q
QUARTERLY REPORT
2025-08-14

WORX filed its 10-Q quarterly report on August 14, 2025. While the filing includes a section dedicated to risk factors, no specific financial highlights or detailed risk descriptions were provided in the available excerpts.

10-Q
QUARTERLY REPORT
2025-05-15
S-1/A
AMENDMENT NO. 1 TO FORM S-1
2025-04-16
8-K
CURRENT REPORT
2025-04-16
10-K
ANNUAL REPORT
2025-03-31
S-1
REGISTRATION STATEMENT
2025-02-13
Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning WORX from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI Chat
Markets
Profile